Personalized Cannabinoid Formulations via AI-driven Genetic Analysis

A next-generation system for tailored cannabinoid formulations using machine learning, genetic analysis, and real-time optimization to revolutionize individualized medicine.

The original patent disclosed cannabinoid formulations aligned with an individual's genotype based on a defined list of polymorphisms. However, this approach has limitations in terms of scalability, accuracy, and adaptability. The new inventive concept addresses these limitations by introducing AI-driven genetic analysis, real-time optimization, and personalized dosing, enabling a more precise and effective approach to cannabinoid therapy.

The system comprises a genetic analysis module, a formulation optimization module, and a manufacturing or dosing module. The genetic analysis module receives genomic data from a subject and generates a personalized cannabinoid profile. The formulation optimization module uses machine learning to optimize the cannabinoid ratios and terpene profiles based on the personalized profile. The manufacturing or dosing module produces or dispenses the optimized formulation in real-time. This integrated system enables personalized cannabinoid formulations that can adapt to an individual's unique genetic profile and environmental factors.

The new claims introduce a paradigm shift by incorporating AI-driven genetic analysis, machine learning, and real-time optimization to create personalized cannabinoid formulations. This approach is novel and non-obvious compared to the original patent, which relied on predefined polymorphisms and manual formulation optimization.

Alternative embodiments may include variations in the machine learning models, genetic analysis tools, and manufacturing or dosing methods. For example, the system could be integrated with wearable devices, mobile applications, or electronic health records to enhance user experience and data collection.

The inventive concept has significant commercial potential in the personalized medicine and cannabis industries. Target markets may include pharmaceutical companies, dispensaries, and healthcare providers seeking to offer tailored cannabinoid therapies to patients. The system's adaptability and real-time optimization capabilities make it an attractive solution for addressing the complexities of individualized medicine.